🔗 Share this article

While the United States proceeds with sweeping changes to its vaccination recommendations, a particular individual appears unexpectedly: Høeg, an American of Danish descent sports physician and public health researcher who initially gained attention by expressing skepticism about coronavirus vaccines during the pandemic and has zeroed in on possible fatalities following COVID-19 vaccination in her recent position at the Food and Drug Administration.

Planned Shifts to Childhood Vaccine Schedule

Agency leaders planned to reveal major revisions to the pediatric immunization program earlier this month, bringing the US with Denmark’s national calendar, according to reports – a substantial departure that would place the US out of step with many the global community with little proof for improved outcomes. This reveal has been pushed back until the new year.

Rather than the top vaccines chief, Dr. Høeg is listed to speak at the event. She was newly appointed temporary leader of the FDA’s CDER, the fifth appointee to head the office this year.

A Shift at the FDA

The acting appointment could signify a closer partnership between the pharmaceutical and biologics centers as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it points to a greater focus upon reevaluating already-approved vaccines at the FDA.

Høeg has frequently advocated for halting certain childhood shot schedules in the US so as to align more in line with Denmark, a society with universal health coverage and a number of inhabitants approximately the population of the state of Wisconsin.

To date comments, she has continued to focus on immunizations – usually the purview of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Questions Over Background

Dr. Høeg has no obvious background in pharmaceutical research, approval processes or management, which has been typical for former directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the commissioner and CBER since March.

“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, stated Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in leading a large organization. She has no expertise in drug approvals.”

Former heads of the center would “understand legal statutes and the underlying principles of drug development”, commented Dr. Janet Woodcock. “Frankly, she doesn’t have the type of experience that prior appointees who ran CBER have had.”

CDER has an enormous range of responsibilities at the agency, the former commissioner pointed out.

“The public just focuses on the innovative therapies, but the generic program authorizes thousands of generic drugs. There’s a biologic copycat branch, OTC medication office and so forth, and all of those need to be managed,” she explained. “The area you overlook, that is precisely what that I always told people is going to bite you.”

Furthermore, a significant leadership aspect to the job, which oversees in excess of 5,000 personnel. “It’s a massive administrative position, if you execute it properly,” she concluded.

Official Statement and Contentious Programs

Regarding concerns about Høeg’s qualifications and whether this selection signifies more teamwork among agency officials on immunizations, a spokesperson said that the “questions rely on incorrect presumptions”.

“Her resume matches the responsibilities of her job,” the spokesperson explained, pointing to the time Høeg spent counseling the agency head on “medication safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Høeg inherits the commissioner’s recently launched expedited review system, a disputed expedited drug-approval program that apparently concerned her preceding directors. “How are these medications being selected for this fast-track system? Who takes the choices?” Dr. Howard asked. “There’s a lot of lack of transparency happening at the agency right now.”

Broadly speaking, he stated, “the agency seems to be moving towards more relaxed regulations of pharmaceuticals, aside from immunizations.”

Established Track Record on Vaccines

With immunizations, Dr. Høeg has a clearer, if problematic, past, Howard have noted. She published a study using non-validated public submissions to assess the incidence of heart inflammation following COVID-19 immunization. She consulted for the Florida surgeon general Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccinations are more dangerous than they are.

Among her “wish list” for the incoming federal leadership featured altering rules for new vaccines and ending “unnecessary” vaccines, she said post-election on a audio program. At the FDA, Dr. Høeg has allegedly floated the idea of barring teenage boys from receiving COVID-19 vaccinations.

“She’s an thorough true believer who starts off with her preconceived notions and works backwards to retrofit the science in a highly disingenuous, dishonest way,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined fellow dissenters, {like|